Research programme: CCR2 receptor antagonists - EPIX

Drug Profile

Research programme: CCR2 receptor antagonists - EPIX

Alternative Names: EPX-102216

Latest Information Update: 16 Oct 2009

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Class Amides; Piperidines
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 01 Oct 2009 EPIX Pharmaceuticals has sold this programme to an undisclosed company
  • 20 Mar 2008 Preclinical trials in Multiple sclerosis in USA (PO)
  • 20 Mar 2008 Preclinical trials in Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top